{"favorite_id": 10162, "calc_type": "diagnostic_criteria", "dosing": false, "full_title_en": "McDonald Criteria for Multiple Sclerosis (2017 Revision)", "short_title_en": "McDonald Criteria (2017 Revision)", "medium_description_en": "<span id=\"docs-internal-guid-b21a6433-7fff-ffea-899a-8e2ef396b96f\">Diagnoses multiple sclerosis.", "short_description_en": "MS diagnosis.", "before_use": "", "instructions_en": "<p dir=\"ltr\">Changes from the 2010 McDonald Criteria:</p>\n<ol>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Presence of <abbr title=\"Cerebrospinal fluid\">CSF</abbr>-specific oligoclonal bands may now substitute for dissemination in time (DIT) even if baseline MRI findings do not meet DIT criteria.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In patients with brainstem or spinal cord attacks, symptomatic lesions may now be included as MRI evidence of dissemination in space (DIS) or DIT.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cortical lesions may now fulfill MRI criteria for DIS (in addition to juxtacortical lesions).</p>\n</li>\n</ol>", "purpose_en": ["Diagnosis"], "disease_en": ["Multiple Sclerosis"], "specialty_en": ["Neurology", "Radiology"], "chief_complaint_en": ["Weakness"], "system_en": ["Neurologic"], "search_abbreviation_en": ["MS", "Mcdonald", "MRI", "dissemination", "time", "space", "multiple sclerosis", "Mcdonald criteria", "2017"], "slug": "mcdonald-criteria-multiple-sclerosis-2017-revision", "seo": {"meta_description_en": "The McDonald Criteria for Multiple Sclerosis (2017 Revision) diagnosis multiple sclerosis.", "keywords_en": "ms criteria, mcdonald criteria, revised mcdonald criteria, r mcdonald, MRI ms diagnosis, mri ms, MS diagnosis criteria, ms diagnostic criteria, mcdonald revised, mcdonald diagnostic criteria, ms attack, clinical attack, clinical diagnosis ms, multiple sclerosis, 2017, 2017 revision"}, "content": {"how_to_use": {"use_case_en": "<p>Patients with suspected&nbsp;MS who have undergone MRI.</p>", "pearls_pitfalls_en": "<ul>\n<li><span id=\"docs-internal-guid-0571dc77-7fff-cf19-4921-8268b0d6a946\">Developed for patients with a typical clinically isolated syndrome deemed unlikely to have other diagnoses, NOT to differentiate MS from other conditions.</li>\n<li>These criteria may help differentiate relapsing-remitting MS from other clinically isolated syndromes that may mimic it.</li>\n</ul>", "why_use_en": ""}, "next_steps": {"advice_en": "<p><span id=\"docs-internal-guid-01a97f38-7fff-f002-d6c8-d05bae5b24e7\">Threshold for additional testing (i.e., spinal cord MRI or CSF examination) should be low, according to the international panel that developed these criteria.</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p><strong>McDonald Criteria (2017):</strong></p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Clinical attacks*</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Number of lesions with objective clinical evidence**</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Additional data needed for diagnosis of MS</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"3\">\n<p dir=\"ltr\">&ge;2</p>\n</td>\n<td>\n<p dir=\"ltr\">&ge;2</p>\n</td>\n<td>\n<p dir=\"ltr\">No additional tests required to demonstrate dissemination in space and time</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">1 (as well as clear-cut historical evidence of a previous attack involving a lesion in a distinct anatomical location)</p>\n</td>\n<td>\n<p dir=\"ltr\">No additional tests required to demonstrate dissemination in space and time</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n<td>\n<p dir=\"ltr\">Dissemination in space demonstrated by an additional clinical attack implicating a different CNS site or by MRI</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">1</p>\n</td>\n<td>\n<p dir=\"ltr\">&ge;2</p>\n</td>\n<td>\n<p dir=\"ltr\">Dissemination in time demonstrated by additional clinical attack or MRI, or presence of CSF-specific oligoclonal bands</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n<td>\n<p dir=\"ltr\">Dissemination in space demonstrated by an additional clinical attack implicating a different CNS site or by MRI and dissemination in time demonstrated by additional clinical attack or MRI, or presence of CSF-specific oligoclonal bands</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">*&ldquo;Clinical attack&rdquo; = monophasic clinical episode with patient-reported symptoms and objective findings reflecting inflammatory demyelinating CNS event (focal or multifocal), subacute or acute, for &ge;24 hrs, with or without recovery, and no fever or infection present. Attack, relapse, exacerbation, and clinically isolated syndrome (first episode) are all synonymous.</p>\n<p dir=\"ltr\">**&ldquo;Objective clinical evidence&rdquo; = abnormality on neurologic exam, imaging (MRI or optical coherence tomography), or visual evoked potentials, corresponding to anatomical location suggested by symptoms.</p>", "more_info_en": "", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30470-2/fulltext", "text": "Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017."}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "", "text": ""}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Alan J. Thompson", "creator_info": {"about_en": "<p>Alan J. Thompson, MD, FMedSci, FRCP, FRCPI, is the dean of the Faculty of Brain Sciences and the Garfield Weston Professor of Clinical Neurology and Neurorehabilitation at the University College London\u00a0in London, England. He is also a senior investigator and faculty member at the National Institute for Health Research. Dr. Thompson\u2019s primary research is focused on predicting outcomes in multiple sclerosis using MRI techniques.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-alan-j-thompson.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed?term=Thompson%20AJ%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "subheading", "subheading": "Clinical attacks", "subheading_instructions": "Must have \u22651 clinical attack"}, {"type": "radio", "label_en": "Number of clinical attacks", "name": "attacks", "options": [{"label": "\u22652", "value": 0}, {"label": "1", "value": 1}], "conditionality": "", "show_points": false, "tips_en": "\u201cClinical attack\u201d = monophasic clinical episode with patient-reported symptoms and objective findings reflecting inflammatory demyelinating CNS event (focal or multifocal), subacute or acute, for \u226524 hrs, with or without recovery, and no fever or infection present; attack, relapse, exacerbation, and clinically isolated syndrome (first episode) are all synonymous", "optional": false}, {"type": "subheading", "subheading": "Lesions", "subheading_instructions": "Must have \u22651 lesion"}, {"type": "radio", "label_en": "Number of lesions with objective clinical evidence", "name": "lesions", "options": [{"label": "\u22652", "value": 0}, {"label": "1", "value": 1}], "conditionality": "", "show_points": false, "tips_en": "\u201cObjective clinical evidence\u201d = abnormality on neurologic exam, imaging (MRI or optical coherence tomography), or visual evoked potentials, corresponding to anatomical location suggested by symptoms", "optional": false}, {"type": "radio", "label_en": "Historical evidence of a previous attack involving a lesion in a distinct anatomical location", "name": "historical", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "attacks == 0 && lesions == 1", "show_points": false, "optional": false}, {"type": "subheading", "subheading": "Additional data", "subheading_instructions": ""}, {"type": "radio", "label_en": "Dissemination in time demonstrated by additional clinical attack or MRI, or presence of CSF-specific oligoclonal bands", "name": "data2", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "attacks == 1", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Dissemination in space demonstrated by an additional clinical attack implicating a different CNS site or by MRI", "name": "data1", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(attacks == 1 && lesions == 1) || (attacks == 0 && lesions == 1 && historical == 0)", "show_points": false, "optional": false}], "md5": "78080e612f41b08163d2aaf80283a5b9", "related_calcs": [{"calcId": 2146, "short_title_en": "EDSS/FSS for Multiple Sclerosis", "slug": "expanded-disability-status-scale-edss-functional-systems-score-fss"}, {"calcId": 2196, "short_title_en": "Modified Fatigue Impact Scale", "slug": "modified-fatigue-impact-scale-mfis"}, {"calcId": 2197, "short_title_en": "Shortened Modified Fatigue Impact Scale", "slug": "shortened-modified-fatigue-impact-scale-mfis"}]}